

# Lamivudine monotherapy in HIV-1-infected patients has been evaluated in a randomized pilot study (E-184V study)

Aids

20, 795-803

DOI: 10.1097/01.aids.0000218542.08845.b2

Citation Report

#	ARTICLE	IF	CITATIONS
1	Issues in the design of trials comparing management strategies for heavily pretreated patients. Current Opinion in HIV and AIDS, 2006, 1, 476-481.	3.8	1
2	Evaluation and management of early virological failure. Current Opinion in HIV and AIDS, 2006, 1, 409-416.	3.8	0
3	Management of the highly experienced patient. Current Opinion in HIV and AIDS, 2006, 1, 424-429.	3.8	0
4	Diminished Selection for Thymidine-Analog Mutations Associated With the Presence of M184V in Ethiopian Children Infected With HIV Subtype C Receiving Lamivudine-Containing Therapy. Pediatric Infectious Disease Journal, 2006, 25, 1049-1056.	2.0	25
5	Clinical trials for heavily pretreated patients: update in 2006. Current Opinion in HIV and AIDS, 2006, 1, 495-501.	3.8	2
6	British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Medicine, 2006, 7, 487-503.	2.2	193
7	Key questions in antiretroviral therapy: Italian Consensus Workshop (2005). Journal of Antimicrobial Chemotherapy, 2006, 57, 1055-1064.	3.0	7
8	Lamivudine Monotherapy in an HIV-Infected Patient With the M184V Mutation. Journal of the International Association of Providers of AIDS Care, 2006, 5, 121-122.	1.2	0
9	Apricitabine: A Novel Deoxycytidine Analogue Nucleoside Reverse Transcriptase Inhibitor for the Treatment of Nucleoside-Resistant HIV Infection. Antiviral Chemistry and Chemotherapy, 2007, 18, 61-70.	0.6	16
10	Improved Interpretation of Genotypic Changes in the HIV Reverse Transcriptase Coding Region That Determine the Virological Response to Didanosine. Journal of Infectious Diseases, 2007, 196, 1645-1653.	4.0	16
11	Association of HIV-1 Replication Capacity With Treatment Outcomes in Patients With Virologic Treatment Failure. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 45, 411-417.	2.1	13
12	Antiretroviral treatment of HIV infection: Swedish recommendations 2007. Scandinavian Journal of Infectious Diseases, 2007, 39, 486-507.	1.5	18
13	Human Immunodeficiency Virus Type 1: Resistance to Nucleoside Analogues and Replicative Capacity in Primary Human Macrophages. Journal of Virology, 2007, 81, 4540-4550.	3.4	25
14	Reply to Vogenthaler. Clinical Infectious Diseases, 2007, 44, 1387-1388.	5.8	1
15	Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2007, 61, 206-209.	3.0	8
16	Long-Term Immunologic and Virologic Responses in Patients with Highly Resistant HIV Infection Who Are Treated with an Incompletely Suppressive Antiretroviral Regimen. Clinical Infectious Diseases, 2007, 45, 1085-1092.	5.8	5
17	Treatment interruption in advanced failing patients. Current Opinion in HIV and AIDS, 2007, 2, 39-45.	3.8	5
18	Partial treatment interruptions. Current Opinion in HIV and AIDS, 2007, 2, 46-55.	3.8	3

#	ARTICLE	IF	CITATIONS
19	Risk of selecting resistance mutations during treatment interruption. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 6-13.	3.8	4
20	Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. <i>Aids</i> , 2007, 21, 1449-1455.	2.2	70
21	Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. <i>Aids</i> , 2007, 21, 721-732.	2.2	85
22	Approach to the Treatment-Experienced Patient. <i>Infectious Disease Clinics of North America</i> , 2007, 21, 85-102.	5.1	9
23	Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. <i>Retrovirology</i> , 2007, 4, 25.	2.0	49
24	Is reduction of viral fitness a valid antiviral approach?. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2007, 4, 267-272.	0.5	0
25	Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors. <i>HIV Medicine</i> , 2007, 8, 529-535.	2.2	16
26	Observational Study on HIV-Infected Subjects Failing HAART Receiving Tenofovir Plus Didanosine as NRTI Backbone. <i>Infection</i> , 2007, 35, 451-456.	4.7	3
27	HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy. <i>Journal of Medical Virology</i> , 2008, 80, 201-208.	5.0	17
28	Perspectives and opportunities for novel antiviral treatments targeting virus fitness. <i>Clinical Microbiology and Infection</i> , 2008, 14, 629-631.	6.0	10
29	Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study. <i>HIV Medicine</i> , 2008, 9, 508-513.	2.2	8
30	Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. <i>Lancet, The</i> , 2008, 371, 1443-1451.	13.7	158
31	Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. <i>Aids</i> , 2008, 22, 1417-1423.	2.2	92
32	Transient Treatment Exclusively Containing Nucleoside Analogue Reverse Transcriptase Inhibitors in Highly Antiretroviral-Experienced Patients Preserves Viral Benefit When a Fully Active Therapy Was Initiated. <i>HIV Clinical Trials</i> , 2008, 9, 387-398.	2.0	7
33	Determination of Clinically Relevant Cutoffs for HIV-1 Phenotypic Resistance Estimates Through a Combined Analysis of Clinical Trial and Cohort Data. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 26-34.	2.1	28
34	Managing Antiretroviral Therapy: Changing Regimens, Resistance Testing, and the Risks from Structured Treatment Interruptions. <i>Journal of Infectious Diseases</i> , 2008, 197, S261-S271.	4.0	24
35	Current Clinical Treatments of AIDS. <i>Advances in Pharmacology</i> , 2008, 56, 27-73.	2.0	8
36	Antiretroviral Therapy in HIV-Infected Patients with Multidrug-Resistant Virus: Applying the Guidelines to Practice. <i>AIDS Patient Care and STDs</i> , 2008, 22, 931-940.	2.5	6

#	ARTICLE	IF	CITATIONS
37	Recent Availability of Two Novel, Fixed Formulations of Antiretroviral Nucleoside Analogues: A 12-Month Prospective, Open-Label Survey of Their Practical Use and Therapeutic Perspectives in Antiretroviral-Naïve and -Experienced Patients. <i>AIDS Patient Care and STDs</i> , 2008, 22, 279-290.	2.5	5
38	Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching. <i>Aids</i> , 2008, 22, 2053-2067.	2.2	26
39	Antiviral drug development: progress and pitfalls. <i>Future Virology</i> , 2008, 3, 529-532.	1.8	0
40	The Place of protease inhibitors in antiretroviral treatment. <i>Brazilian Journal of Infectious Diseases</i> , 2009, 13, 371-374.	0.6	10
41	In Vivo Fitness Cost of the M184V Mutation in Multidrug-Resistant Human Immunodeficiency Virus Type 1 in the Absence of Lamivudine. <i>Journal of Virology</i> , 2009, 83, 2038-2043.	3.4	76
42	Survival of HIV-1 Infected Multidrug-Resistant Patients Recycling Enfuvirtide After a Previous Failure. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 179-184.	2.1	4
43	Minority drug-resistant HIV-1 variants: transmission and response to antiretroviral therapy. <i>HIV Therapy</i> , 2009, 3, 55-61.	0.6	0
44	Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure. <i>AIDS Research and Therapy</i> , 2009, 6, 30.	1.7	9
45	Multidrug resistance: a clinical approach. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 499-506.	3.8	3
46	The risk of HIV drug resistance following implementation of pre-exposure prophylaxis. <i>Current Opinion in Infectious Diseases</i> , 2010, 23, 621-627.	3.1	24
47	The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. <i>Aids</i> , 2010, 24, 1917-1922.	2.2	30
48	Antiretroviral Therapy in HIV-Infected Infants and Children. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 360-363.	2.0	4
49	Current and future management of treatment failure in low- and middle-income countries. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 83-89.	3.8	17
50	Estimated average annual rate of change of CD4+ T-cell counts in patients on combination antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 563-570.	1.0	12
51	Monitoring Antiretroviral Therapy in Resource-Limited Settings: Balancing Clinical Care, Technology, and Human Resources. <i>Current HIV/AIDS Reports</i> , 2010, 7, 168-174.	3.1	15
52	Clinical management of HIV-1 resistance. <i>Antiviral Research</i> , 2010, 85, 245-265.	4.1	77
53	Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. <i>HIV Medicine</i> , 2010, 11, 510-518.	2.2	82
54	Human immunodeficiency virus type 1 fitness and tropism: concept, quantification, and clinical relevance. <i>Clinical Microbiology and Infection</i> , 2010, 16, 1532-1538.	6.0	18

#	ARTICLE	IF	CITATIONS
55	Prior Therapy Influences the Efficacy of Lamivudine Monotherapy in Patients with Lamivudine-resistant HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 51-58.	2.1	9
56	International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase. Antimicrobial Agents and Chemotherapy, 2010, 54, 1520-1525.	3.2	9
57	Comparison of Antiviral Activity of Regimens Containing Nucleos(t)ide (NUC) Pairs in HIV-Infected Patients Initiating REScue Therapy (The NUCREST Study). HIV Clinical Trials, 2010, 11, 294-302.	2.0	1
58	Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy. The Cochrane Library, 2010, , CD006517.	2.8	14
59	Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: A pilot randomised trial. Journal of Clinical Virology, 2010, 47, 253-257.	3.1	4
61	Antiretroviral therapy and management of HIV infection. Lancet, The, 2010, 376, 49-62.	13.7	348
62	Lamivudine for the treatment of HIV. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 105-114.	3.3	28
63	Pre-Exposure Prophylaxis and Antiretroviral Resistance: HIV Prevention at a Cost?. Clinical Infectious Diseases, 2011, 53, 1265-1270.	5.8	94
64	Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committee. Canadian Journal of Infectious Diseases and Medical Microbiology, 2011, 22, 52-60.	1.9	6
65	Transmitted Drug Resistance in the CFAR Network of Integrated Clinical Systems Cohort: Prevalence and Effects on Pre-Therapy CD4 and Viral Load. PLoS ONE, 2011, 6, e21189.	2.5	28
66	Prior Therapy Influences the Efficacy of Lamivudine Monotherapy in Patients With Lamivudine-Resistant HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, e34-e35.	2.1	1
67	Lower CD4 Cell Count and Higher Virus Load, but Not Antiretroviral Drug Resistance, Are Associated with AIDS-Defining Events and Mortality: An ACTG Longitudinal Linked Randomized Trials (ALLRT) Analysis. HIV Clinical Trials, 2011, 12, 79-88.	2.0	8
68	Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption. Clinical Microbiology and Infection, 2011, 17, 928-934.	6.0	20
69	High efficacy of lopinavir/râ€based secondâ€line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. Journal of the International AIDS Society, 2011, 14, 14-14.	3.0	33
70	It is time to consider thirdâ€line options in antiretroviralâ€experienced paediatric patients?. Journal of the International AIDS Society, 2011, 14, 55-55.	3.0	15
71	Longitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption. Infection, 2011, 39, 121-126.	4.7	12
72	<i>No pol</i> mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy. Journal of Medical Virology, 2011, 83, 391-398.	5.0	1
73	Single-Boosted Protease Inhibitor versus Double-Boosted Protease Inhibitors for the Salvage Therapy in HIV-Infected Patients. Journal of the International Association of Providers of AIDS Care, 2011, 10, 105-110.	1.2	0

#	ARTICLE	IF	CITATIONS
74	Residual Activity of Two HIV Antiretroviral Regimens Prescribed without Virological Monitoring. Antimicrobial Agents and Chemotherapy, 2011, 55, 4575-4580.	3.2	2
75	The Role of Inactive Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Salvage Therapy for Drug-Resistant HIV-1 Infection in the Era of New Classes and New Generation Antiretrovirals. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, e46-e48.	2.1	1
76	Differential Persistence of Transmitted HIV-1 Drug Resistance Mutation Classes. Journal of Infectious Diseases, 2011, 203, 1174-1181.	4.0	125
77	British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Medicine, 2012, 13, 1-6.	2.2	149
78	7.0â€€,Managing virological failure. HIV Medicine, 2012, 13, 47-56.	2.2	0
79	Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy. Aids, 2013, 27, 553-561.	2.2	21
80	Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa. Aids, 2013, 27, 2943-2951.	2.2	61
81	Antiretroviral treatment, management challenges and outcomes in perinatally HIVâ€€infected adolescents. Journal of the International AIDS Society, 2013, 16, 18579.	3.0	159
82	Virological failure and drug resistance during first line antiâ€€retroviral treatment in Indonesia. Journal of Medical Virology, 2013, 85, 1394-1401.	5.0	14
83	Use of Nucleoside Reverse Transcriptase Inhibitorâ€€only Regimens in HIV-infected Children and Adolescents. Pediatric Infectious Disease Journal, 2013, 32, e370-e376.	2.0	1
84	7.0â€€,Managing virological failure. HIV Medicine, 2014, 15, 48-57.	2.2	2
85	Short Communication: Focal Encephalitis Related to Viral Escape and Resistance Emergence in Cerebrospinal Fluid in a Patient on Lopinavir/Ritonavir Monotherapy with Plasma HIV-1 RNA Suppression. AIDS Research and Human Retroviruses, 2014, 30, 984-987.	1.1	27
87	Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: results from the VERITAS study (TMC114HIV4054). HIV Clinical Trials, 2015, 16, 111-116.	2.0	9
88	Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and raceâ€€ethnicity determine the degree of regimen complexity. HIV Clinical Trials, 2015, 16, 147-156.	2.0	12
90	Systems Approach to targeted and long-acting HIV/AIDS therapy. Drug Delivery and Translational Research, 2015, 5, 531-539.	5.8	16
91	Lamivudine Monotherapy. Pediatric Infectious Disease Journal, 2016, 35, e199-e205.	2.0	6
92	Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda. Tropical Medicine and International Health, 2016, 21, 928-935.	2.3	39
93	HIV-1 drug resistance and resistance testing. Infection, Genetics and Evolution, 2016, 46, 292-307.	2.3	215

#	ARTICLE	IF	CITATIONS
94	British HIV Association guidelines for the treatment of HIV-positive adults with antiretroviral therapy 2015. <i>HIV Medicine</i> , 2016, 17, s2-s104.	2.2	78
95	Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1346-1351.	3.0	3
96	Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12) Tj ETQq0,0,0 rgBT /Overlock 1 e384-e392.	4.7	63
97	The interaction between equipoise and logistics in clinical trials: A case study. <i>Clinical Trials</i> , 2017, 14, 314-318.	1.6	6
98	Resistance matters in EARNEST. <i>Lancet HIV</i> , 2017, 4, e323-e324.	4.7	6
99	The Association between Detected drug Resistance Mutations and CD4 <sup>+</sup> T-Cell Decline in HIV-Positive Individuals Maintained on a Failing Treatment Regimen. <i>Antiviral Therapy</i> , 2018, 23, 105-116.	1.0	3
100	Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 78, 125-135.	2.1	59
101	Rethinking recycling nucleoside reverse transcriptase inhibitors in HIV treatment. <i>Aids</i> , 2018, 32, 835-840.	2.2	1
102	geno2pheno[ngs-freq]: a genotypic interpretation system for identifying viral drug resistance using next-generation sequencing data. <i>Nucleic Acids Research</i> , 2018, 46, W271-W277.	14.5	37
103	A Therapeutic Perspective of Living with Human Immunodeficiency Virus/AIDS in 2017. <i>Nursing Clinics of North America</i> , 2018, 53, 97-110.	1.5	5
104	Lamivudine monotherapy as a holding regimen for HIV-positive children. <i>PLoS ONE</i> , 2018, 13, e0205455.	2.5	4
105	Dual antiretroviral therapy with tenofovir (TDF) and darunavir/ritonavir (DRV/RTV) in an HIV-1 positive patient: a case report, review, and meta-analysis of the literature on dual treatment strategies using protease inhibitors in combination with an NRTI. <i>Infection</i> , 2018, 46, 599-605.	4.7	2
106	Use and Outcomes of Antiretroviral Monotherapy and Treatment Interruption in Adolescents With Perinatal HIV Infection in Asia. <i>Journal of Adolescent Health</i> , 2019, 65, 651-659.	2.5	0
107	What Should We Do When HIV-positive Children Fail First-line Combination Antiretroviral Therapy? A Comparison of 4 ART Management Strategies. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 400-405.	2.0	4
108	Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 35-42.	2.5	19
109	Clinical trials of antiretroviral treatment interruption in HIV-infected individuals. <i>Aids</i> , 2019, 33, 773-791.	2.2	34
110	Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. <i>Lancet HIV</i> , 2019, 6, e116-e127.	4.7	84
111	Virologic suppression in patients with a documented M184V/I mutation based on the number of active agents in the antiretroviral regimen. <i>SAGE Open Medicine</i> , 2020, 8, 205031212096057.	1.8	1



#	ARTICLE	IF	CITATIONS
112	Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO). EBioMedicine, 2020, 55, 102779.	6.1	28
113	Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV. Journal of Antimicrobial Chemotherapy, 2020, 75, 2986-2993.	3.0	6
114	Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation. HIV Medicine, 2020, 21, 309-321.	2.2	3
115	Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients. International Journal of Antimicrobial Agents, 2020, 55, 105893.	2.5	28
116	Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-naïve Ugandan children. Acta Paediatrica, International Journal of Paediatrics, 2020, 109, 2706-2716.	1.5	5
117	New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 98-103.	2.1	1
118	Antiretroviral Drug Treatment of Individuals that Used Preexposure Prophylaxis (PrEP) Before Diagnosis. Current Treatment Options in Infectious Diseases, 2021, 13, 141-152.	1.9	0
119	The clinical challenges of lifetime HAART. , 2008, , 421-462.		2
120	In Vitro HIV-1 Evolution in Response to Triple Reverse Transcriptase Inhibitors & In Silico Phenotypic Analysis. PLoS ONE, 2013, 8, e61102.	2.5	12
121	Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial. PLoS ONE, 2017, 12, e0178075.	2.5	1
122	Country review: Germany. , 2008, , 119-136.		0
123	Evaluation of HIV-1 viral load and genotypic resistance assays for resource-limited settings. Afrika Focus, 2008, 21, .	0.2	0
124	Clinical Implications of Reverse Transcriptase Inhibitor Resistance. , 2009, , 589-619.		0
125	HIV/AIDS and Opportunistic Illnesses. , 2009, , 373-401.		1
126	Changing antiretroviral therapy in children. Southern African Journal of HIV Medicine, 2009, 10, 85.	0.9	0
127	Antiretroviral therapy for HIV. , 2010, , 556-566.		1
128	In Vivo Validation of a Bioinformatics Based Tool to Identify Reduced Replication Capacity in HIV-1. Open Medical Informatics Journal, 2010, 4, 225-232.	1.0	0
129	Simplification of Antiretroviral Therapy (ART). , 0, , .		0



#	ARTICLE	IF	CITATIONS
130	Treatment Failure and Resistance. , 2015, , 1-7.		0
131	Treatment Failure and Resistance. , 2018, , 2047-2053.		0
132	Fitness Cost of Antiretroviral Drug Resistance Mutations on the pol Gene during Analytical Antiretroviral Treatment Interruption among Individuals Experiencing Virological Failure. Pathogens, 2021, 10, 1425.	2.8	3
133	The renaissance of fixed dose combinations: Combivir. Therapeutics and Clinical Risk Management, 2007, 3, 579-83.	2.0	11
135	Lamivudine and Indinavir/Ritonavir Maintenance Therapy in Highly Pretreated HIV-Infected Patients (Vista Anrs 109). Antiviral Therapy, 2006, 11, 889-900.	1.0	4
136	Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients. Antiviral Therapy, 2009, 14, 339-347.	1.0	26
137	A Randomized Trial to Evaluate Continuation versus Discontinuation of Lamivudine in Individuals Failing A Lamivudine-Containing Regimen: The Colate Trial. Antiviral Therapy, 2006, 11, 761-770.	1.0	31
138	Evolution driven by a varying host environment selects for distinct HIV-1 entry phenotypes and other informative variants. Frontiers in Virology, 0, 3, .	1.4	0
139	Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis. Open Forum Infectious Diseases, 2023, 10, .	0.9	1